Dashboard: Access to the BPaL regimen

TB Alliance launched a webpage to provide information on national-level access to the BPaL regimen - a three-drug, 6-month, all-oral regimen composed of bedaquiline, pretomanid and linezolid for the treatment of highly drug-resistant forms of TB.

The tool can filter countries by region or the following access pathways:

  • Regulatory approval
  • Named Patient Access Program
  • Global Drug Facility catalog of TB medicines
  • Operational research

Explore the tool here.

To subscribe to the Weekly Newsletter of new posts, enter your email here:

By TB Alliance

Published: Aug. 5, 2021, 12:15 a.m.

Last updated: Aug. 8, 2021, 11:16 p.m.

Print Share